Globus Medical Inc. (GMED) expected to report EPS of $0.59 for the current quarter

In the latest session, Globus Medical Inc. (NYSE: GMED) closed at $53.07 down -0.58% from its previous closing price of $53.38. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 818646 shares were traded. GMED stock price reached its highest trading level at $53.35 during the session, while it also had its lowest trading level at $52.38.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



For a deeper understanding of Globus Medical Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 45.97. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 6.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 15 when Lemaitre Dan sold 43,450 shares for $56.98 per share. The transaction valued at 2,475,977 led to the insider holds 10,800 shares of the business.

Pfeil Keith W sold 29,167 shares of GMED for $2,262,426 on Feb 02. The SVP, Chief Financial Officer now owns 0 shares after completing the transaction at $77.57 per share. On Dec 01, another insider, Huller Kelly, who serves as the SVP, GC, Corporate Secretary of the company, sold 7,500 shares for $75.00 each. As a result, the insider received 562,501 and left with 0 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 5.86B and an Enterprise Value of 5.36B. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.84, and their Forward P/E ratio for the next fiscal year is 20.47. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.03 while its Price-to-Book (P/B) ratio in mrq is 2.78. Its current Enterprise Value per Revenue stands at 5.01 whereas that against EBITDA is 17.03.

Stock Price History:

Over the past 52 weeks, GMED has reached a high of $80.04, while it has fallen to a 52-week low of $50.92. The 50-Day Moving Average of the stock is 56.22, while the 200-Day Moving Average is calculated to be 63.57.

Shares Statistics:

For the past three months, GMED has traded an average of 1.44M shares per day and 1.29M over the past ten days. A total of 100.28M shares are outstanding, with a floating share count of 76.58M. Insiders hold about 1.08% of the company’s shares, while institutions hold 99.82% stake in the company. Shares short for GMED as of May 14, 2023 were 7.7M with a Short Ratio of 7.70M, compared to 5.78M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 7.67% and a Short% of Float of 9.74%.

Earnings Estimates

There are 14 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.59 for the current quarter, with a high estimate of $0.67 and a low estimate of $0.56, while EPS last year was $0.56. The consensus estimate for the next quarter is $0.57, with high estimates of $0.61 and low estimates of $0.54.

Analysts are recommending an EPS of between $2.44 and $2.25 for the fiscal current year, implying an average EPS of $2.32. EPS for the following year is $2.59, with 14 analysts recommending between $2.74 and $2.49.

Revenue Estimates

A total of 12 analysts believe the company’s revenue will be $278.9M this quarter.It ranges from a high estimate of $288.83M to a low estimate of $276M. As of the current estimate, Globus Medical Inc.’s year-ago sales were $263.65M, an estimated increase of 5.80% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $270.48M, an increase of 6.40% over than the figure of $5.80% in the same quarter last year. There is a high estimate of $276.9M for the next quarter, whereas the lowest estimate is $262M.

A total of 14 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $1.13B, while the lowest revenue estimate was $1.1B, resulting in an average revenue estimate of $1.12B. In the same quarter a year ago, actual revenue was $1.02B, up 9.30% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $1.21B in the next fiscal year. The high estimate is $1.24B and the low estimate is $1.19B. The average revenue growth estimate for next year is up 8.60% from the average revenue estimate for this year.